ERBB2 and small cell lung carcinoma: Many mechanisms of resistance to EGFR-TKIs, such as the T790M mutation, ERBB2 amplification, MET alterations, C797X, SCLC transformation, and oncogene fusions, have been reported (Oxnard et al.